Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:57:16.347Z.
Calculation as of: 2026-10-06T15:57:16.347Z.
Quote observation: 2026-10-06T15:54:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-05-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$83.04M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.48M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
Market Cap
$85.01M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.78M
Price/OCF Ratio
N/A
TTM Avg
17.74
3Y Avg
16.00
5Y Avg
17.53
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediciNova, Inc. (MNOV) | $82.73M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.53M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | N/A | 786.57 | 786.57 | 786.57 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.45M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.13M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | N/A | 17.74 | 16.00 | 17.53 |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.57M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2015-05-11 | 121.41 |
| 2015-05-08 | 120.21 |
| 2015-05-07 | 121.41 |
| 2015-05-06 | 123.51 |
| 2015-05-05 | 120.21 |
| 2015-05-04 | 118.41 |
| 2015-05-01 | 114.80 |
| 2015-04-30 | 116.60 |
| 2015-04-29 | 112.40 |
| 2015-04-28 | 115.40 |
| 2015-04-27 | 113.00 |
| 2015-04-24 | 122.91 |
| 2015-04-23 | 119.61 |
| 2015-04-22 | 119.01 |
| 2015-04-21 | 122.61 |
| 2015-04-20 | 122.61 |
| 2015-04-17 | 133.73 |
| 2015-04-16 | 149.06 |
| 2015-04-15 | 105.48 |
| 2015-04-14 | 104.28 |
| 2015-04-13 | 101.58 |
| 2015-04-10 | 104.28 |
| 2015-04-09 | 101.88 |
| 2015-04-08 | 104.40 |
| 2015-04-07 | 100.07 |
| 2015-04-06 | 102.18 |
| 2015-04-02 | 103.68 |
| 2015-04-01 | 106.69 |
| 2015-03-31 | 105.18 |
| 2015-03-30 | 107.89 |
| 2015-03-27 | 106.69 |
| 2015-03-26 | 99.77 |
| 2015-03-25 | 98.57 |
| 2015-03-24 | 102.48 |
| 2015-03-23 | 102.48 |
| 2015-03-20 | 106.08 |
| 2015-03-19 | 106.69 |
| 2015-03-18 | 102.78 |
| 2015-03-17 | 98.27 |
| 2015-03-16 | 97.67 |
| 2015-03-13 | 100.98 |
